NCAM1 and Down syndrome: However, in contrast to our survey this study also included a lot of patients with Down syndrome (11/29 patients) who are known to have lower CD19+ and CD3−CD16+ and/or CD56+ cells [6], precluding an appreciation for the possibility of underlying immunodeficiency in patients with non-Down, chromosomal syndromes.